ADME Prediction with KNIME: Development and Validation of a Publicly Available Workflow for the Prediction of Human
Gabriela Falcón-Cano1, Christophe Molina2, Miguel Ángel Cabrera-Pérez1,3
1Unit of Modeling and Experimental Biopharmaceutics, Centro de Bioactivos Quı́micos, Universidad Central "Marta Abreu" de las Villas, Santa Clara, Villa Clara 54830, Cuba.
Abstract:
In silico prediction of human oral bioavailability is a relevant tool for the selection of potential drug candidates and for the rejection of those molecules with less probability of success during the early stages of drug discovery and development. However, the high variability and complexity of oral bioavailability and the limited experimental data in the public domain have mainly restricted the development of reliable in silico models to predict this property from the chemical structure. In this study we present a KNIME automated workflow to predict human oral bioavailability of new drug and drug-like molecules based on five machine learning approaches combined into an ensemble model. The workflow is freely accessible and allows the quick and easy prediction of oral bioavailability for new molecules. Users do not require any knowledge or advanced experience in machine learning or statistical modeling to automatically obtain their predictions, increasing the potential use of the present proposal.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
On...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Measurement of Bioavailability: Pharmacokinetic Methods
Bioavailability Study Design: Healthy Subjects Versus Patients
Analysis of Population Pharmacokinetic Data
